Alan Murray, Co-founder and CEO of Conceivable Life Sciences – Interview Series

Interviews Alan Murray, Co-founder and CEO of Conceivable Life Sciences – Interview Series Published July 31, 2026 By Antoine Tardif, CEO & Founder of Unite.AI Add Unite.AI to your preferred sources on Google Alan Murray, Co-founder and CEO, Conceivable Life Sciences – is an engineer and serial entrepreneur with more than three decades of experience spanning technology, machine learning, hardware, logistics and company building. Before launching Conceivable, he co-founded TMRW Life Sciences, where he helped develop an automated platform for managing and safeguarding frozen eggs and embryos used in in vitro fertilization (IVF). Murray is also a co-founder and partner at Coriolis Ventures and has helped establish companies across digital advertising, hospitality and life sciences, including Integral Ad Science (IAS ), Dstillery and NeueHouse. At Conceivable, he serves as both a strategic leader and the chief architect of AURA, overseeing the integration of robotics, advanced imaging and machine learning into fertility laboratory workflows.Conceivable Life Sciences is a biotechnology company developing AURA, an automation-assisted IVF laboratory designed to coordinate the complex processes involved in creating, cultivating and preserving embryos. Rather than automating a single procedure, the platform integrates robotics, software, advanced optics, artificial intelligence and laboratory equipment across the IVF workflow, while maintaining digital traceability and allowing embryologists to retain control over clinical decisions. Conceivable aims to use this standardized approach to reduce variability, expand laboratory capacity and make fertility treatment more accessible and affordable to families who currently face high costs or limited access to specialist care.You previously co-founded TMRW Life Sciences, where you helped introduce automation into the storage and management of frozen eggs and embryos. What did that experience teach you about the limitations of today’s fertility infrastructure, and what ultimately convinced you to found Conceivable Life Sciences and tackle the more complex challenge of automating embryo creation?At TMRW, we automated how eggs and embryos are stored and tracked once they exist. It solved a real problem, chain of custody in cryopreservation is unforgiving, and getting that right matters enormously to patients. But it also showed me the limits of what storage automation alone could fix. The bottleneck in IVF was never really what happens after the embryo is made. It’s the making of it. That work still depends on a small number of highly trained embryologists doing manual, repetitive, sub-micron precision tasks by hand, and the outcome varies by who’s holding the pipette that day.When I started TMRW, the fertility storage market was still treated as a niche corner of reproductive medicine. I didn’t see it that way. Delayed parenthood was becoming the norm, more people were freezing eggs and sperm earlier, employers were starting to add fertility preservation to benefits packages, and the LGBTQ+ and single-parent communities were building families through egg and sperm banking at a scale the industry hadn’t planned for. All of that pointed to a storage and tracking problem that was about to